Cannabics Pharmaceuticals Inc is the developer of the world’s first cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer based on the company's novel and proprietary formulation Cannabics™️ RCC-33.
The company's groundbreaking research and development are carried out in its in-house state of the art drug discovery facilities using proprietary High Throughput Screening (HTS) technology and advanced bioinformatics.